Hand-foot skin reaction (HFSR) is the most common and most serious adverse event induced by multikinase inhibitors (MKIs). About 9%–62% patients receiving sorafenib or sunitinib treatments develop HFSR. Severe HFSR leads to dose reduction or suspension of MKI treatment.
Twenty-seven HFSR patients induced by sorafenib or sunitinib were included. SAS statistical software was used and patients were randomly divided into 2 groupx: experimental group (14 cases) and control group (13 cases). Tong-Luo-San (TLS) was locally administered for 7 days (20 min, bid), compared with placebo as blank control. Observation parameters included pain numerical rating scale (NRS) scores, HFSR grading of National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE), clinical grading of National Comprehensive Cancer Network (NCCN) grade in Impact of Pain Measurement Scores, total effective rate, analgesic efficacy rate and adverse events.
NRS scores, HFSR grade and NCCN grade in impact of pain measurement scores decreased obviously after 7 days' treatment in the experimental group (P
TLS significantly reduced HFSR grade, alleviated pain and improved patients' quality of life. It was also safe and convenient to use.
Clinical trial identification
Legal entity responsible for the study
China-Japan Friendship Hospital
Ministry of Science and Technology of People's Republic of China
All authors have declared no conflicts of interest.